Please login to the form below

Not currently logged in
Email:
Password:

Lovaza

This page shows the latest Lovaza news and features for those working in and with pharma, biotech and healthcare.

GSK holds on to older products

GSK holds on to older products

No suitable buyer found for portfolio of established medicines. Lovaza is one of several of GSK's drugs in its established products portfolio. ... The decline was primarily due to the onset of generic competition for the company's fish oil drug Lovaza,

Latest news

  • FDA approves AZ’s fish oil drug FDA approves AZ’s fish oil drug

    Once launched Epanova will enter a competitive for market for hypertriglyceridemia medicines, including BASF/Pronova's Omacor/Lovaza, another omega-3 fatty acid product. ... Omacor/Lovaza achieved end-user sales of around $1.4bn in 2011 and is sold by

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    Israel-based Teva Pharmaceutical Industries has won US FDA approval for a generic equivalent to GlaxoSmithKline's fish-oil derived cardiovascular product Lovaza and will launch it immediately. ... GSK acquired US rights to Lovaza - which was originally

  • GSK starts recovery from China crisis as growth returns GSK starts recovery from China crisis as growth returns

    That prediction disappointed some analysts, although it is thought to be a conservative estimate based on potential generic competition to older products such as cardiovascular drug Lovaza (omega-3-acid ethyl

  • Amarin slides as FDA panel votes against fish oil therapy Amarin slides as FDA panel votes against fish oil therapy

    One of the claims made by Amarin for Vascepa is that it reduces triglycerides without raising LDL-C, which could differentiate it from Lovaza/Omacor (omega-3-acid ethyl esters), another ... Lovaza sales in the first half of this year were around $500m

  • Witty says Chinese bribery probe will impact GSK Witty says Chinese bribery probe will impact GSK

    Generic rivals impacted epilepsy treatment Lamictal (lamotrigine), down 8 per cent to £63m, while heart disease drug Lovaza (omega-3-acid ethyl esters) held firm at £161m despite competition.

More from news
Approximately 2 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2012 Pharma deals during November 2012

    a cash buyout valued at $845m. Pronova supplies the active ingredient in GSK's triglyceride lowering omega-3 drug Lovaza and, in addition, is developing competitor formulations – the most advanced being ... 900. Pronova BioPharma / BASF. Acquisition.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics